Plain-English translation of NCT07100873 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing , a new type of cell therapy designed to treat rheumatoid arthritis in people whose disease has not responded well to standard medications. The treatment uses specially engineered immune cells to help calm the overactive immune response that causes joint damage. Researchers are comparing two different preparation methods to see which works best and causes fewer side effects.
Standard rheumatoid arthritis medications don't work for everyone, leaving some patients with ongoing pain, swelling, and joint damage. This trial is exploring whether this medication—a newer approach using engineered immune cells—could help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would go through a screening period to confirm you're eligible, then receive preparation medications followed by an infusion of the engineered cells. The trial has different phases comparing two preparation approaches to see which is safest and most effective. After treatment, you would have regular clinic visits and phone check-ins over an extended follow-up period so doctors can carefully monitor how you respond and watch for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Adicet Therapeutics
Enrollment target
~25 participants
Started
October 2025
Primary completion
March 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Adicet Medical Monitor
Adicet Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.